Last $309.07 USD
Change Today -17.70 / -5.42%
Volume 7.1M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Business Wire  07/31/2014 6:54 AM ET
RBCC 3D Bioprinting Partner Awarded Prestigious Grant

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Jul. 31, 2014-- The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.

The NIH's Small Business Innovation research (SBIR) program is a set-aside program for small business concerns to engage in research and development that has the potential for commercialization. Nano3D was awarded a Phase I SBIR grant for work associated with its recent proposal, titled “Novel 3D high-content/throughput assay with mobile device-based data acquisition.”

Alongside RBCC, n3D is working to market and develop the BiO Assay: the world's first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market.

Nano3D's winning proposal details a 3D model that is rapid, quantitative, and representative for high-throughput toxicity testing to meet these needs by magnetically printing 3D cultures.

“We're immensely gratified that the NIH recognizes the unprecedented research potential of the Bio Assay,” said RBCC CEO Kimberly Palmer. “This effective, affordable technology could soon replace traditional in vitro and animal toxicity tests permanently.”

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations such as the BiO Assay to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:  RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit  www.RainbowBioSciences.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Source: Rainbow Coral Corp.

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
info@rainbowbiosciences.com

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $309.07 USD -17.70

Industry News

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.